ISSN 2564-7784 | E-ISSN 2564-7040
Original Article
The relationship between admission HbA1c level and infarct-related artery patency in ST elevation myocardial infarction patients
1 Ankara Numune Education and Research Hospital, Department of Cardiology, Ankara, Türkiye  
2 Atatürk Education and Research Hospital, Department of Cardiology, Ankara, Türkiye  
3 Ankara Yıldırım Beyazıt University, Faculty of Medicine, Deapertment of Cardiology, Ankara, Turkey  
Eur J Ther ; : -
DOI: 10.5152/EurJTher.2019.18055
Key Words: HbA1c; mean platelet volume; ST elevation myocardial infarction; infarct-related artery patency, primary percutaneous coronary intervention

Background: Patency of infarct - related artery (IRA) in patients with ST segment elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (pPCI) is associated with lower mortality and better clinical outcome. In this study, the relationship between admission haemoglobin A1c (HbA1c) and IRA patency before mechanical reperfusion in patients with STEMI was investigated.


Methods: A total of 140 consecutive patients with STEMI undergoing pPCI within 12 hours from symptom onset were retrospectively evaluated. IRA patency was assessed by the Thrombolysis In Myocardial Infarction (TIMI) flow grade and patients initially were divided into 2 groups based on the TIMI flow grade. Impaired flow was defined as TIMI grades 0 and 1 and normal flow or patency was defined as TIMI 2 and 3. Patients were divided into three groups based on admission HbA1c levels as group I (HbA1c ≤ 5.6%), group II (HbA1c 5.6 – 6.5%), and group III (HbA1c ≥ 6.5%).


Results: Among 140 patients, 46 (32.8 %) had pre-pPCI TIMI 2 and 3 flow in IRA. The IRA patency was found to be similar in all 3 HbA1c groups (p= 0.269). Admission HbA1c levels were similar in both IRA groups (p= 0.314). In multivariate regression analysis, only MPV (OR: 0.589, 95% CI: 0.365-0.951, p= 0.030) was significantly and independently associated with IRA patency.


Conclusions: HbA1c is not an independent predictor of the IRA patency in STEMI patients treated with pPCI. However, MPV is a simple, low-cost and easily accessible parameter and might be used as a predictor of IRA patency.

Key Words
AVES | Copyright © 2019 European Journal of Therapeutics | Latest Update: 18.09.2019